Cellect Biotechnology Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Cellect Biotechnology Ltd., a foreign private issuer based in Kfar Saba, Israel, for the month of August 2018. The filing incorporates by reference a press release dated August 20, 2018, regarding intellectual property developments.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory milestone rather than financial performance.
Material Changes
The primary material event reported is the receipt of a Notice of Allowance for a patent covering the company's stem cell selection technology in Korea. This represents a significant advancement in the company's intellectual property portfolio.
Guidance, Outlook, and Risks
The filing incorporates "Forward Looking Statements" from the attached press release by reference into the company's Registration Statements on Form S-8 and Form F-3. No specific financial guidance, management commentary on operations, or detailed risk factors are provided within the text of this specific Form 6-K.
Key Facts for Investor Verification
- Verify the scope and commercial applicability of the stem cell selection technology patent allowed in Korea.
- Confirm the status of the company's Registration Statements (Nos. 333-214817, 333-220015, 333-225003, 333-219614, and 333-212432) referenced in the filing.
- Review the full text of the August 20, 2018 press release (Exhibit 99.1) for details on the patent and forward-looking statements not included in this summary.